You can find a selection of our global flagship products on this page. However, please note that our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations; thus, in compliance with such regulations, we cannot provide detailed information about our prescription medicines on this website. Visit the applicable local Daiichi Sankyo affiliate company websites via the "Worldwide" link below to find product information in your region or country. Finally, any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

Worldwide

Flagship Products

ENHERTU®

trastuzumab deruxtecan
(fam-trastuzumab deruxtecan-nxki in the United States only)

ENHERTU (5.4 mg/kg) is a HER2 directed antibody drug conjugate (ADC) approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy, based on results from the DESTINY-Breast03 trial. ENHERTU also is approved in several countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens based on the results from the DESTINY-Breast01 trial.

ENHERTU (5.4 mg/kg) is approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridization (ISH)-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy, based on the results of the DESTINY-Breast04 trial.

ENHERTU (5.4 mg/kg) is approved in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy based on the results of the DESTINY-Lung02 trial.

ENHERTU (6.4 mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

Available RegionUS, EU, UK, Japan & ASCA (Asia, South and Central America)

Select your country

TURALIO®

pexidartinib

TURALIO is a CSF-1R inhibitor approved in the United States for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. based on the ENLIVEN trial.

Available RegionUS

Select your country

VANFLYTA®

quizartinib

VANFLYTA is a FLT3 inhibitor approved in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), as detected by an MHLW-approved test, based on the QuANTUM-R trial.

Available RegionJapan

Select your country

Injectafer®

ferric carboxymaltose injection

Treatment for iron deficiency anemia

Available RegionUS

Select your country

LIXIANA®/SAVAYSA®

edoxaban

Oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor.
More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, EDOSURE, which is comprised of more than 10 RCTs (randomized, controlled trials), non-interventional studies and registries, including completed, ongoing and future research.

Available RegionUS, EU, Japan, ASCA

Select your country

MINNEBRO®

esaxerenone

Antihypertensive agent

Available RegionJapan

Select your country

OLMETEC®/OLMETEC PLUS®; REZALTAS®; SEVIKAR®/SEVIKAR HCT®

olmesartan medoxomil

Antihypertensive agent

Available RegionEU, Japan, ASCA

Select your country

NILEMDO®/NUSTENDI®

bempedoic acid / fixed-dose combination of bempedoic acid and ezetimibe

NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol, and can be combined with other lipid-lowering therapies to help lower cholesterol even further.

NUSTENDI® is a fixed-dose combination tablet of bempedoic acid and ezetimibe which combines two complementary ways of reducing colesterol.

Available RegionEU

Select your country

CANALIA®

teneligliptin, canagliflozin

Treatment for Type 2 diabetes mellitus

Available RegionJapan

Select your country

EMGALITY®

galcanezumab-gnlm

Treatment for migraine attacks

Available RegionJapan

Select your country

PRALIA®

denosumab (genetic recombination)

Treatment for osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis

Available RegionJapan

Select your country

RANMARK®

denosumab (genetic recombination)

Treatment for bone complications caused by bone metastases from tumors

Available RegionJapan

Select your country

TARLIGE®

mirogabalin

Treatment for pain

Available RegionJapan

Select your country

TENELIA®

teneligliptin hydrobromide hydrate

Treatment for Type 2 diabetes mellitus

Available RegionJapan

Select your country

Venofer®

iron sucrose

Treatment for iron deficiency anemia

Available RegionUS

Select your country

Vimpat®

lacosamide

Anti-epileptic agent

Available RegionJapan

Select your country

Influenza HA Vaccine

Influenza HA vaccine

Vaccine for influenza infection

Available RegionJapan

Select your country

Adsorbed Cell Culture-derived Influenza Vaccine (H5N1)

Adsorbed cell culture-derived influenza vaccine (H5N1)

Vaccine for influenza infection

Available RegionJapan

Select your country

Measles Rubella Combined Vaccine

Measles Rubella combined vaccine

Vaccine for Measles/Rubella infection

Available RegionJapan

Select your country

Mumps Vaccine

Mumps vaccine

Vaccine for Mumps infection

Available RegionJapan

Select your country

ENHERTU®

trastuzumab deruxtecan
(fam-trastuzumab deruxtecan-nxki in the United States only)

ENHERTU (5.4 mg/kg) is a HER2 directed antibody drug conjugate (ADC) approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy, based on results from the DESTINY-Breast03 trial. ENHERTU also is approved in several countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens based on the results from the DESTINY-Breast01 trial.

ENHERTU (5.4 mg/kg) is approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridization (ISH)-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy, based on the results of the DESTINY-Breast04 trial.

ENHERTU (5.4 mg/kg) is approved in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy based on the results of the DESTINY-Lung02 trial.

ENHERTU (6.4 mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

Available RegionUS, EU, UK, Japan & ASCA (Asia, South and Central America)

Select your country

TURALIO®

pexidartinib

TURALIO is a CSF-1R inhibitor approved in the United States for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. based on the ENLIVEN trial.

Available RegionUS

Select your country

VANFLYTA®

quizartinib

VANFLYTA is a FLT3 inhibitor approved in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), as detected by an MHLW-approved test, based on the QuANTUM-R trial.

Available RegionJapan

Select your country

Injectafer®

ferric carboxymaltose injection

Treatment for iron deficiency anemia

Available RegionUS

Select your country

LIXIANA®/SAVAYSA®

edoxaban

Oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor.
More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, EDOSURE, which is comprised of more than 10 RCTs (randomized, controlled trials), non-interventional studies and registries, including completed, ongoing and future research.

Available RegionUS, EU, Japan, ASCA

Select your country

MINNEBRO®

esaxerenone

Antihypertensive agent

Available RegionJapan

Select your country

OLMETEC®/OLMETEC PLUS®; REZALTAS®; SEVIKAR®/SEVIKAR HCT®

olmesartan medoxomil

Antihypertensive agent

Available RegionEU, Japan, ASCA

Select your country

NILEMDO®/NUSTENDI®

bempedoic acid / fixed-dose combination of bempedoic acid and ezetimibe

NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol, and can be combined with other lipid-lowering therapies to help lower cholesterol even further.

NUSTENDI® is a fixed-dose combination tablet of bempedoic acid and ezetimibe which combines two complementary ways of reducing colesterol.

Available RegionEU

Select your country

CANALIA®

teneligliptin, canagliflozin

Treatment for Type 2 diabetes mellitus

Available RegionJapan

Select your country

EMGALITY®

galcanezumab-gnlm

Treatment for migraine attacks

Available RegionJapan

Select your country

PRALIA®

denosumab (genetic recombination)

Treatment for osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis

Available RegionJapan

Select your country

RANMARK®

denosumab (genetic recombination)

Treatment for bone complications caused by bone metastases from tumors

Available RegionJapan

Select your country

TARLIGE®

mirogabalin

Treatment for pain

Available RegionJapan

Select your country

TENELIA®

teneligliptin hydrobromide hydrate

Treatment for Type 2 diabetes mellitus

Available RegionJapan

Select your country

Venofer®

iron sucrose

Treatment for iron deficiency anemia

Available RegionUS

Select your country

Vimpat®

lacosamide

Anti-epileptic agent

Available RegionJapan

Select your country

Influenza HA Vaccine

Influenza HA vaccine

Vaccine for influenza infection

Available RegionJapan

Select your country

Adsorbed Cell Culture-derived Influenza Vaccine (H5N1)

Adsorbed cell culture-derived influenza vaccine (H5N1)

Vaccine for influenza infection

Available RegionJapan

Select your country

Measles Rubella Combined Vaccine

Measles Rubella combined vaccine

Vaccine for Measles/Rubella infection

Available RegionJapan

Select your country

Mumps Vaccine

Mumps vaccine

Vaccine for Mumps infection

Available RegionJapan

Select your country